secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106246
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455
--------------------------------------------------------------------------------

- Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.
- Raised $15.9M in Q2; extended cash runway into late Q4 2025; secured up to $25M equity line.
- Introduced APVO455, a Nectin-4 x CD3 bispecific for bladder, breast, NSCLC, head & neck cancers.
- Mipletamig achieved 85% remission rate (11/13) in frontline AML; no CRS reported.
- Shares outstanding grew to 3,224,156 vs 72,922 at Dec 31, 2024 due to equity raises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/0000950170-25-106246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/apvo-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer